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Hyaluronan (HA) is a glycosaminoglycan composed by repeating units of D-glucuronic acid (GlcUA) and
N-acetylglucosamine (GlcNAc) that is ubiquitously present in the extracellular matrix (ECM) where it has a
critical role in the physiology and pathology of several mammalian tissues. HA represents a perfect environment
in which cells can migrate and proliferate. Moreover, several receptors can interact with HA at cellular
level triggering multiple signal transduction responses. The control of the HA synthesis is therefore critical
in ECM assembly and cell biology; in this review we address the metabolic regulation of HA synthesis. In
contrast with other glycosaminoglycans, which are synthesized in the Golgi apparatus, HA is produced at the
plasma membrane by HA synthases (HAS1-3), which use cytoplasmic UDP-glucuronic acid and UDP-N-
acetylglucosamine as substrates. UDP-GlcUA and UDP-hexosamine availability is critical for the synthesis of
GAGs, which is an energy consuming process. AMP activated protein kinase (AMPK), which is considered a
sensor of the energy status of the cell and is activated by low ATP:AMP ratio, leads to the inhibition of HA
secretion by HAS2 phosphorylation at threonine 110. However, the most general sensor of cellular nutritional
status is the hexosamine biosynthetic pathway that brings to the formation of UDP-GlcNAc and intracellular
protein glycosylation by O-linked attachment of the monosaccharide β-N-acetylglucosamine (O-GlcNAcylation)
to speciﬁc aminoacid residues. Such highly dynamic and ubiquitous protein modiﬁcation affects serine 221
residue of HAS2 that lead to a dramatic stabilization of the enzyme in the membranes.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The complex molecular structure that surrounds cells in tissues is
deﬁned as extracellular matrix (ECM) which has been reported to have
many critical functions in determining the cellular microenvironment.
A large body of evidence supports the concept that ECM not only acts
in the structural architecture of the cells and tissues, but also regulates
cell behavior in both physiological and pathological conditions
controlling nutrient and waste exchanges, cell–cell and cell–matrix
interactions, and diffusion of signaling molecules. Nowadays, the active
role of ECM in cell physiology and pathology determination, for instance,
proliferation, movements and differentiation of the cells as well as
the stem cell niche is becoming more evident. ECM is also critical in
cell dysfunctions that characterize many pathologies as cancer or
cardiovascular diseases (Vigetti et al., 2006a; Akita et al., 2008;
Acloque et al., 2009).
Among the different components of ECM, polysaccharides (i.e.,glycos-
aminoglycans, GAGs) have the highest variability and represent the
most dynamic structures in tissues. In fact, several chemicalmodiﬁcations
as epimerization, acetylation, O-, and N-sulfation are critical to determine
the properties of chondroitins, heparan sulfate, and keratan. A
plethora of enzymes are known to tailor GAG molecules during
pathophysiological processes (Afratis et al., 2012). A further degree
of variability is represented by the proteoglycan (PG) core protein, to
which the GAG chains are linked. In fact, PGs can have several isoforms
and can be differently modiﬁed by proteases and other post-
translational modiﬁcations. Hyaluronan (HA) is an atypical GAG being
not covalently bond to any PG core proteins, not epimerizated and not
sulfated, although tumor necrosis factor alpha-stimulated protein 6
and its covalent binding to HA can mediate the transfer of the heavy
chain of inter alpha trypsin inhibitor to \COOH of HA leading to
a complex known as Serum-derived Hyaluronan-associated Protein
(SHAP), that has proinﬂammatory properties and is involved in many
pathologies (Jiang et al., 2011).
HA is simply composed by the disaccharide unit D-glucuronic acid
(GlcUA) and D-N-acetyl-glucosamine (GlcNAc) linked by alternating
β-1,4 and β-1,3 glycosidic bonds. HA is considered a molecule rich in
biological information being the polymer length critical to determine
HA effects (Stern et al., 2006). In fact, the number of HA disaccharide
repetitions can greatly vary in determining the polymer molecular
mass that ranges from 5 to 10,000 kDa. Further, high molecular
weight HA can be fragmented in short oligosaccharides by different
mechanisms including degrading enzymes (i.e., hyaluronidases), and
free radicals (Stern et al., 2006). Moreover, low molecular mass HA
can be directly synthesized by dysregulation of HA synthases (HASes)
aswell as due to an alter precursor availability. Therefore, the rheostatic
effects of HA largely depend on the size of the polymeric chain. Further,
several proteinswith receptor functions have been described to bindHA
directly affecting cell behavior (Jiang et al., 2011; Vigetti et al., 2011b). In
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the light of these premises, HA cannot be considered a merely space
ﬁlling molecule but a ubiquitous microenvironment component able
to trigger different cell signaling cascades and to modulate many
physiological and pathological processes. This review focuses on the
ﬁne mechanism that links cellular metabolism and HA synthesis also
describing the known post-translational modiﬁcations of HASes in
mammals.
1.1. HA synthases
In mammals HA is synthesized by three different isoenzymes
named HAS 1, 2, and 3. HASes are plasma membrane proteins that
use cytoplasmic UDP-GlcNAc and UDP-GlcUA as precursors to
polymerize the HA chain and to extrude it out of the cell without the
necessity of a primer or an anchor protein or lipid. However puriﬁcation
experiments revealed that bacterial HAS (which shares several structural
similarities with mammalian enzymes (Weigel and DeAngelis, 2007)) is
strictly associatedwith cardiolipin and the catalytic activity is dependent
on such lipid (Weigel et al., 1997). Although the crystallographic data
are not yet available, HASes would have a complex architecture.
In fact, a single protein codes for many functions as binding of
two distinct UDP-sugars and binding of two distinct HA acceptor or
donor species. Moreover HASes transfer two different sugars in two
different linkages, catalyze repetitive sugar polymerization, and
transfer HA across the membrane (Weigel and DeAngelis, 2007;
Hubbard et al., 2012).
Little is known about HASes structure, topological in silico analyses
revealed that Class 1 mammalian and Streptococcal HASes have 2
N-terminal transmembrane domains and several of C-terminal
transmembrane domains or membrane associated domains (Jiang
et al., 2011). In Fig. 1 are reported the predicted structural organization
of mammals (Fig. 1A) and Streptococcal HASes (Fig. 1B). These domains
are responsible for the catalytic activities of these proteins (Heldermon
et al., 2001). On the other hand, the only member of Class 2 HAS,
expressed by Pasteurella multocida, has a shorter C-terminal domain
with only 4 transmembrane regions and 2 membrane associated
domains. Interestingly, only a limited number of pathogenic bacteria
show the ability to produce HA,which is used by these bacteria to shield
themselves from the host immune system (DeAngelis, 1999). The
cytosolic domain shares similarities with chitin synthases highlighting
the importance of this portion of the protein for the catalysis. The
overexpression of HAS2 and 3 lead to the formation of hetero and
homodimers in Chinese hamster ovary (CHO) cells (Karousou et al.,
2010) and this observation is consistent with the evidence that HAS
activity resides in a large protein complex in plasma membranes
(Asplund et al., 1998).
HASes possess different biochemical properties (Itano and Kimata,
2002). HAS1 is less catalytically active than HAS2, which, in turn,
is intrinsically less active than HAS3. Moreover, HAS1 and HAS2
synthesize a polymer of highmolecular weightwhereas HAS3 produces
shorter chains (~2 × 106 Da vs ~2 × 105 Da, respectively) (Itano et al.,
1999). Interestingly, the lower intrinsic activity of HAS1 comes from
the fact that it cannot produce HA when the cellular level of
UDP-sugars is low (Rilla et al., 2013).
Many growth factors, cytokines, and other signaling molecules
control the transcription of HAS genes and are recently reviewed
elsewhere (Tammi et al., 2011). Once transcribed, to reach the plasma
membrane, HAS proteins have to be synthesized in the endoplasmic
reticulum and to follow the secretory pathway. Interestingly,
microsomal membrane preparations, without plasma membrane
contaminations, showed the capacity to synthesize HA in vitro. These
properties are evident after several cell treatments that modulate ER
stress, protein N-glycosylation and phosphorylation (Vigetti et al.,
2009a). These latter evidences suggest that HASes enzymes, once
translated, are subjected to a ﬁne regulation that is largely unknown,
nevertheless can be reasonable to hypothesize that modiﬁcations of
HASes can have a critical role in HASes activity. Moreover, evidences
in vitro on puriﬁed bacterial (P. multocida) HAS showed that a
monodispersed HA chain can be obtained by ﬁnely tuning the reaction
stoichiometry. In fact the molar ratio of precursors and acceptor
molecules has an important role in enzyme kinetics (Jing and
DeAngelis, 2004; DeAngelis, 2008). This point highlights the crucial
role of UDP-sugar precursors and, therefore, of the entire cellmetabolism
that produces HAS substrates.
2. Role of UDP-GlcUA and cellular energy homeostasis
UDP-GlcUA has many functions in mammalian cells in addition to
being a component of the GAGs with the exception of keratan sulfate.
In fact, UDP-GlcUA is the donor substrate for glucuronidation reactions
that take place in liver to detoxify the organism and in other cell types
(Vigetti et al., 2009b). Moreover, UDP-GlcUA can be decarboxylated to
UDP-xylose which is critical for the linking of GAGs to proteoglycan
core proteins.
To investigate the role of UDP-GlcUA in GAG synthesis, our group
overexpressed UDP-glucose dehydrogenase, the enzymes involved in
the oxidation of UDP-glucose to form UDP-GlcUA (Fig. 2), in human
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Fig. 1.A. Schematic representation of Class 1mammalHASwith 6 transmembrane domains
and 2 membrane associated domains. B. Schematic representation of Streptococcal Class 1
HAS with 4 transmembrane domains and 2 membrane associated domains (B, upper
panel). In the lower panel there is a representation of Class 1 HAS in which the two
cytoplasmic loops and the central pore for HA chain extrusion in the extracellular space
are highlighted.
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cells and found an increment in the production of HA without altering
the other GAG synthesis (Vigetti et al., 2006b). This point is of crucial
importance because it could be an evidence that the UDP-sugar
concentrations can vary in the cytosol and not inside the Golgi, where
the sulfated GAGs are synthesized. The high afﬁnity transporters of
sugar nucleotides located on the Golgi membranes (Berninsone et al.,
2001;Hoﬂich et al., 2004) are critical inmaintaining a high concentration
of UDP-sugars inside the Golgi, even if the cytosolic availability of such
precursors is lowor limiting. In this condition the onlyGAG to be affected
by UDP sugar availability is HA, as HASes use precursors directly from
the cytosolic pools. On the other hand, an increase of cytosolic UDP-
sugars should have a minor impact on GAG synthesis in the Golgi
as the saturation of the transporters, but have a signiﬁcant effect on
HA production. Therefore HA is the only GAG to be directly affected by
UDP-sugar metabolism. Interestingly, an increase of UDP-glucose
dehydrogenase (UGDH) was described during aging and linked with
HA accumulation and signaling alteration (Vigetti et al., 2008b;
Simpson et al., 2010; Cargill et al., 2012).
Other experiments in chondrocytes showed that also UDP-glucose
pyrophosphorylase (UPP), the enzyme that catalyzes the formation of
UDP-glucose from glucose-1 phosphate and UTP (Fig. 2) is critical for
HA synthesis. In fact, the overexpression of UPP leads to an increase of
HA accumulation (Magee et al., 2001). Besides its role in GAG synthesis,
UDP-glucose is a critical substrate for glycogen synthesis. On this basis,
it is clear that the fate of UDP-glucose has to be ﬁnely tuned, in fact
all the reactions that involve UDP-glucose are essentially irreversible
in all cellular conditions. As glycogen is a key component for cellular
energy homeostasis, our hypothesis is that the energy charge
(i.e., ATP:AMP ratio) can regulate UDP-GlcUA availability and GAG
synthesis.
The main sensor of the energy status of the cell is represented by
AMP activated protein kinase (AMPK) (Hardie, 2004). AMPK is a
heterotrimeric cytosolic enzyme consisting of a catalytic subunit (α)
and two regulatory subunits (β and γ). This kinase is allosterically
activated by an increase of the AMP:ATP ratio (Towler and Hardie,
2007), which occurs under conditions of cellular stress or energy
deﬁciency, such as hypoxia, ischemia, and glucose deprivation (Towler
and Hardie, 2007). AMPK is also activated through the phosphorylation
of a conserved threonine in its activation loop (threonine 172) by
upstream kinases as LKB1 (Hardie et al., 2006). When the ATP:AMP
ratio decreases, AMPK inhibits anabolic processes and induces catabolic
pathways in order to restore ATP levels (Towler and Hardie, 2007). By
altering gene expression or by direct phosphorylation of several pivotal
enzymes, AMPK regulates different cellular metabolic pathways,
including glycolysis, gluconeogenesis, lipid metabolism, and protein
synthesis.
GAG synthesis needs energy not just in terms of ATP, but also
because it requires molecules involved in energy production as acetyl-
CoA.Moreover, other criticalmolecules in cellmetabolismare necessary
for GAG synthesis, as glutamine, PAPS, and UTP, all depending on
several metabolisms which regulate the synthetic pathway of sugars,
amino acids and nucleotides. Moreover, the synthesis of UDP-GlcUA,
producing two NADH molecules, can interfere with the NAD+:NADH
ratio, linking glucuronic acid synthesis with cell reducing potential.
Interestingly, AMPK inhibited HA synthesis without altering the
sulfated GAG production in human aortic smooth muscle cells (Vigetti
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Fig. 2. Schematic representation of the UDP-GlcUA biosynthetic pathway and the hexosamine biosynthetic pathway. Glucose and glucosamine (GlcN) enter the cell through the GLUT
transporters. UDP-glucose pyrophosphorylase (UGPP) and dehydrogenase (UGDH) bring to the formation of UDP-glucose (UDP-G) and UDP-GlcUA, respectively, starting from glucose
1-phosphate. UDP-GlcUA and UDP-GlcNAc can be directly used for the synthesis of HA by HAS enzymes located in the plasma membrane or can be transported inside the ER/Golgi for
the synthesis of other glycoconjugates, especially proteoglycans.
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et al., 2011a). Moreover, in human dermal ﬁbroblast, the chemical
activation of AMPK with AICAR, which mimics AMP inside the cells,
slightly induces HAS2 messenger accumulation (Yamane et al., 2011)
suggesting a complex and cell speciﬁc regulation of HAS2 transcription
or HAS2 mRNA stability.
It was suggested that HASes activity is phospholipid-dependent
(Weigel and DeAngelis, 2007) and AMPK can regulate the lipid
microenvironment around HAS enzyme and, indirectly, modulate
HAS activity or stability. We found that HAS2 enzymatic activity is
dramatically inhibited after AMPK activation and this was due to the
phosphorylation of threonine 110 of HAS2 (Vigetti et al., 2011a). As
this residue is a conserved consensus for AMPK and the threonine 110
is located in the cytoplasmic loop of HAS2, this ﬁnding leads to the
possibility that AMPK directly can modify HAS2 whereas the other
enzymes for GAGs synthesis, located in the Golgi and not accessible
to AMPK, are unaffected by AMPK. This aspect is conﬁrmed by
experiments using the AMPK activators, as AICAR, metformin or
2-deoxyglucose, which inﬂuenced only HA synthesis and not sulfated
GAG production (Vigetti et al., 2011a). Interestingly the levels of
mRNAs coding for the three HASes were not altered by AMPK (Vigetti
et al., 2011a).
A previous study reported the phosphorylation of HAS3 without
any effect on enzyme functionality (Goentzel et al., 2006), whereas
another work clearly showed that ERK-mediated serine phosphorylation
of all the three HASes increased their speciﬁc activity (Bourguignon et al.,
2007). Interestingly, the treatments of plasmamembranes ormicrosomal
membranes with phosphatases or N-glycosidase F revealed that also
HAS activity in internal vesicles can be modulated (Vigetti et al., 2009a).
These ﬁndings suggest that HAS proteins have different and complex
regulatorymechanisms inwhich several post-translationalmodiﬁcations
in different sites can increase or decrease the enzymatic activity also
during the secretory pathway. Moreover, a further level of regulation
can derive from the observation that HAS2 and 3 can make homo and
heterodimers, and that HAS2 activity can bemodulated by ubiquitination
at Lys190 (Karousou et al., 2010). Such results suggest that HASes, and
HAS2 in particular, can be complex proteins with several possibilities
for post-translational modiﬁcations capable of modulating enzymatic
activity.
These observations suggest that the covalent modiﬁcations of the
enzymes can be obtained very fast, and the cell reaction to the stimuli
can take place in minutes. This concept introduces the idea that HASes
can be considered “ready to use” enzymes, that means that their fast
turnover and their presence in microsomal domain allow the cells to
modulate very efﬁciently and rapidly the HA synthesis.
3. Role of UDP-GlcNAc and protein O-GlcNAcylation
Little is known about the availability of UDP-GlcUA andUDP-glucose
when AMPK is activated, as in the case of nutrient shortage. In smooth
muscle cells, UGPP and UGDH expressions were not modiﬁed after
treatments with AICAR and metformin (Vigetti et al., 2011a). This
ﬁnding can be explained considering that UDP-glucose and UDP-
GlcUA are critical not only for HA synthesis, but also for all other sulfated
GAGs, glycogen and other glycoconjugates that are all necessary for cell
survival. Noteworthy, a proteomic study revealed that UGPP can be a
target of AMPK in pigs, enhancing the level of complexity of this issue
(Hedegaard et al., 2004).
The other critical sugar nucleotide for the synthesis of GAGs is
UDP-GlcNAc (Fig. 2) which can be easily converted to UDP-GlcNAc by
UDP-galactose 4-epimerase (Thoden et al., 2001). UDP-GlcNAc is one
of the most abundant UDP-sugars within the cell (ranging from
100 μM to low millimolar, values comparable to ATP) and it is known
that the UDP-GlcNAc concentration can greatly ﬂuctuate (Tomiya
et al., 2001; Marshall et al., 2004). Such variability depends not only
on the amount of glucose that enters in the hexosamine biosynthetic
pathway (HBP) (typically 2–5%) (McClain and Crook, 1996), but also
depends on other pathways which regulate fatty acid, nucleotide and
aminoacid metabolisms (Hanover et al., 2012). In fact, the hexosamine
biosynthetic pathway integrates the nutrient status of the cell by
utilizing glucose, acetyl-CoA, glutamine, and UTP to produce UDP-
GlcNAc which can be considered an efﬁcient nutrient sensor (Fig. 3).
In addition to glycoconjugates, UDP-GlcNAc can be used to
glycosylate nucleo- and cytoplasmic proteins with β-O-linked GlcNAc
(O-GlcNAcylation) (Butkinaree et al., 2010). O-GlcNAcylation is a
reversible post-translational modiﬁcation of serine/threonine that often
alternates or competes with protein phosphorylation and is controlled
by two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAc hydrolase
(OGA) (Hart et al., 2007; Hart et al., 2011) (Fig. 3). O-GlcNAcylation
regulates many cellular functions including signaling, gene expression,
degradation, and trafﬁcking (Hart et al., 2007) and, interestingly, appears
to be particularly sensitive to physiological ﬂux of the UDP-GlcNAc pools
(Love et al., 2010). Interestingly, a recent paper by Rilla and collaborators
demonstrates the large range of UDP-sugar contents presented by
different cell types, and showed a correlation between the expression
of different HASes and the UDP-sugars (Rilla et al., 2013).
Increments of UDP-GlcNAc due to glucosamine or glucose uptake
greatly induced the accumulation of GAGs (HA and chondroitins) in
the medium of human smooth muscle cells (Vigetti et al., 2012).
Such GAG increase is also permitted by a concomitant augment of
UDP-GlcUA with a not yet known mechanism (Jokela et al., 2011).
Interestingly the increment of O-GlcNAcylation without altering UDP-
GlcNAc concentration (i.e., by inhibiting OGA with O-(2-acetamido-2-
deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAC))
signiﬁcantly induced only in HA production (Vigetti et al., 2012). This
speciﬁc effect on HA can be ascribed to the O-GlcNAcylation of serine
221 of HAS2 which greatly stabilizes the enzyme in the membrane.
HAS2 has a very rapid turnover with a calculated half-life of 17 min
due to 26S proteasomal degradation (Vigetti et al., 2012). This
instability, togetherwith a very low level of HAS2 transcript, contributes
to render HAS2 a very low expressed enzyme in cells. O-GlcNAcylation
of HAS2 in the serine 221 is located in the cytosolic loop, does not alter
the enzymic activity and increases the enzyme half-life to more than
5h, permitting an increased HA synthesis (Vigetti et al., 2012).
The mechanism of HAS2 proteasomal degradation is complex and
requires additional processes considering the several transmembrane
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Fig. 3. Schematic representation of proteinO-GlcNAcylation.UDP-GlcNAc concentration in
cell cytosol depends on several pathways and is critical in regulating OGT activity. OGT
catalyzes the transfer of the GlcNAc moiety from UDP-GlcNAc to the hydroxyl group of
threonine or serine. OGA hydrolyzes the GlcNAc from the O-GlcNAcylation to form
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domains of HAS2 and its localization in the plasma membrane. Other
mechanisms can be encountered considering the presence of active
HAS2 in intracellular vesicles that can be part of the secretory pathway,
or the possible internalization of the enzyme by endocytosis or
plasma membrane recycling (Vigetti et al., 2009a). Several plasma
membrane proteins are known to be ubiquitinated and degraded by
the proteasome (Sepp-Lorenzino et al., 1995; Jeffers et al., 1997),
whereas other plasma membrane proteins were internalized by
endocytosis, and degraded by lysosomes (Bonifacino and Weissman,
1998). HAS2 is known to be poly- and mono-ubiquitinated and, while
monoubiquitination seems to be involved in enzyme dimerization,
polyubiquitination does not seem directly related to proteasomal
degradation (Karousou et al., 2010). Recently, it was described that
OGA can promote the degradation of surface lipid droplet proteins via
the proteasome (Keembiyehetty et al., 2012) and, therefore, it can
have a role in the regulation of HAS2 stability. Moreover, OGT is also
present in the endoplasmic reticulum (ER) (Sakaidani et al., 2012),
which could regulate the HAS2 folding process or its escape from the
ER. Proteasomal degradation is typically associated with protein
misfolding events within the ER, and this could also be involved in the
regulation of HAS2. ER stress is known to modulate HA synthesis by
alteringHAS activity (Vigetti et al., 2009a). Finally, the process to deliver
HAS2 to theproteasome is a complexmechanismand occurs in different
cell conditions. Based on these considerations, to shed light on this issue
additional studies are required, addressing speciﬁcally the HASes
traveling throughout the cells and their covalent modiﬁcations and
catalytic activities.
From a pathological point of view, the regulation of HAS2
by O-GlcNAcylation can have important therapeutic consequences
considering that the excess of glucose can lead to a dramatic increase
of UDP-GlcNAc and HA (in particular in cells where the uptake of
glucose is insulin independent). Clinical and experimental evidences
show that in hyperglycemic patients and in streptozotocin-induced
diabetes animals there is evidence of HA accumulation both in plasma
and in vascular wall (Heickendorff et al., 1994; McDonald et al., 2007).
Since HA has pro-atherosclerotic properties (Vigetti et al., 2008a),
stimulating cellular migration, and proliferation and modulating
inﬂammation, it could be linked with macro- and microvascular
diseases that represent a common complication in diabetic patients.
4. Conclusions
GAGs are a critical component of cellular microenvironment and
are able to modulate cell behavior directly by binding to speciﬁc
receptors/proteins or indirectly by sequestering growth factors and
other signalingmolecules. As HA is ubiquitous in the body, it is involved
in many physiological and pathological processes. Recently, several
evidences described a critical role of HA in inﬂammation, shedding
light on this GAG role in human pathology and revealing its pivotal
role inmodulating immune cell differentiation, adhesion and activation.
A deeper understanding of the speciﬁc mechanisms that regulate
HA synthesis in vivo represents a new pharmacological target to
treat pathologies in which the increase (i.e. cancer, diabetes) or
decrease (joint disorders) of HA synthesis can have effects of clinical
relevance.
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